• Incorporated in Singapore as the first cord blood bank offering private cord blood banking services.
  • Launched the first Cordlife facility at Camden Medical Centre in Singapore.
  • Released the company’s first cord blood unit for a five-year-old boy suffering from Leukaemia.
  • Acquired Cytomatrix, a stem cell research company specialising in cell expansion technology.
  • First and only cord blood bank in Southeast Asia to be listed on the Australian Securities Exchange (ASX).
  • Became a founding member of the Asia Pacific Cord Blood Banks Consortium (APCBBC).
  • Established marketing offices in Indonesia and Thailand.
  • Marketing office established in the Philippines.
  • Successfully acquired BioCell, the second largest private cord blood bank in Australia.
  • First overseas Cordlife processing and storage facility launched in Hong Kong.
  • Received accreditation from American Association of Blood Banks (AABB) for the facility in Singapore. AABB's Accreditation Program strives to improve the quality and safety of collecting, processing, testing, distributing and administering blood and blood products by assessing the quality and operational systems in place within the facility.
  • Incorporated Cordlife Sciences India Pvt. Ltd., which was officially launched by Singapore Senior Minister and former Prime Minister Mr. Goh Chok Tong in Kolkata.
  • Sponsored the first cystic fibrosis cord blood collection in Australia.
  • Acquired 20 percent of Netherlands tissue engineering company, PharmaCell BV.
  • Globally recognised as “Technology Pioneer” by the World Economic Forum.
  • Launched the first and only DEPKES licensed cord blood processing and storage facility in Indonesia.
  • Cordlife Hong Kong awarded the ISO 9001:2000 certification.
  • BioCell received Australia’s Therapeutic Goods Administration license (TGA).
  • Received AABB re-accreditation for new Singapore flagship facility located in Singapore Science Park II.
  • Launched “Cordlife Cares” programme, the first CSR (Corporate Social Responsibility) programme, in Singapore.
  • Cordlife sales office opened in Indonesia’s third largest city, Medan & also a second office in Kowloon, Hong Kong which is strategically located opposite Hong Kong Baptist Hospital that holds the record for the country’s highest number of private deliveries.
  • Cordlife India started its operational venture.
  • Introduction of the only fully automated cord blood processing technology, Singapore & Hong Kong.
  • Appointed as Quality Advisor to Beijing Cord Blood Bank, one of the largest cord blood banks in China.
  • Cordlife India received the ISO 9001:2008 certification for its quality management system.
  • In December, Cordlife secured strategic stake in China Stem Cell (South) Co. Ltd. with US$ 10 million investment.
  • Global Launch of the “Cordlife Quality Guarantee” which assures a matched replacement cord blood unit for US$25,000 compensation.
  • Released cord blood unit for the first autologous treatment for Neuroblastoma in Singapore.
  • First in the Philippines to incorporate Sepax, a fully automated system for cord blood processing.
  • Group CEO, Dr Steven Fang, honoured as the Most Outstanding Entrepreneur by APEA.
  • Cordlife Indonesia received ISO 9001:2008 certification.
  • Released cord blood unit for the second cerebral palsy treatment in Singapore.
  • First in India to introduce Umbilical Cord Blood service for the cryo-preservation of two cell lines.
  • Released cord blood unit for the first autologous treatment of Neuroblastoma in Hong Kong.
  • Released cord blood unit for the first sibling-related treatment of Thalassaemia major in West Bengal.
  • Cordlife Philippines achieved the ISO 9001:2008 certification.
  • Cordlife India also received ISO 9001:2008 re-certification.
  • In 2013, Cordlife India successfully attained accreditation from AABB, the world-class standard in cord blood banking.
  • Cordlife India introduced the first fully automated processing technology for cord blood processing.
  • Acquired significant stake in China Cord Blood Corporation, China’s largest network of stem cell banks.
  • Ventured into Malaysia with significant stake in Stemlife Berhad. Malaysia’s largest stem cell banking operator.
  • Cordlife India received WHO GMP certification for the first time.
  • Cordlife tied up with Duke Medicine to treat autistic patients who have stored their cord blood.
  • Cordlife India started its journey of becoming a multi-product company targeting mother & baby by introducing Metascreen™ - A metabolic screening service for new-borns, in India.
  • Cordlife India received AABB re-accreditation for the second time.
  • Cordlife Singapore received accreditation from FACT-Netcord which ensures the global standard of excellence in patient care and laboratory practices. Cordlife is one out of the six private cord blood banks worldwide that is double-accredited and the first in Southeast Asia to achieve the dual-accreditation status with AABB and FACT (The Foundation for the Accreditation of Cellular Therapy).
  • Launched the Cordlife-Jalan Kayu Pre-School Headstart Fund in Singapore with a sponsorship of $150K to give young children from low-income families a chance in pre-school education.
  • Partnered with autism and epilepsy treatment pioneer, Dr Michael Chez from Sutter Medical Group and Sutter Neuroscience Institute in the continued study of autologous cord blood cells treatments.
  • Received the 16th SIAS Investors’ Choice Award (Runnerup), Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category.
  • Honoured by Forbes Asia as one of the “Best Under a Billion” companies in November 2015.
  • Awarded by Frost & Sullivan as the Stem Cell banking Company of the Year in Singapore
  • Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries.
  • Cordlife India received accreditation from College of American Pathologists (CAP)
  • Awarded by Frost & Sullivan as the Stem Cell banking Company of the Year in Asia.
  • Cordlife India clinches the Gold as the Best Social Media Healthcare Brand in an online voting survey conducted by Social Samosa, a renowned Online Media Publication.